{"id":40241,"date":"2000-09-01T12:04:00","date_gmt":"2000-09-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie"},"modified":"2000-09-01T12:04:00","modified_gmt":"2000-09-01T10:04:00","slug":"nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/","title":{"rendered":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie"},"content":{"rendered":"<p>Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[128,2195,129,4517,139,2656,324,6854,644],"class_list":["post-40241","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-ass","tag-azetylsalizylsaeure","tag-classics-studie","tag-clopidogrel","tag-koronar-stent","tag-stent","tag-thrombotisch-thrombozytopenische-purpura","tag-ticlopidin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2000-09-01T10:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie\",\"datePublished\":\"2000-09-01T10:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/\"},\"wordCount\":335,\"keywords\":[\"Acetylsalicyls\u00e4ure\",\"ASS\",\"Azetylsalizyls\u00e4ure\",\"CLASSICS-Studie\",\"Clopidogrel\",\"Koronar-Stent\",\"Stent\",\"Thrombotisch-thrombozytopenische Purpura\",\"Ticlopidin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/\",\"name\":\"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2000-09-01T10:04:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief","og_description":"Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2000-09-01T10:04:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie","datePublished":"2000-09-01T10:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/"},"wordCount":335,"keywords":["Acetylsalicyls\u00e4ure","ASS","Azetylsalizyls\u00e4ure","CLASSICS-Studie","Clopidogrel","Koronar-Stent","Stent","Thrombotisch-thrombozytopenische Purpura","Ticlopidin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/","name":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2000-09-01T10:04:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40241"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}